Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJSE:920729's EV-to-FCF is ranked worse than 70.53% of 319
companies
in the Biotechnology industry
Industry Median: 16.98
vs BJSE:920729: 35.49
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guangdong Winsun Bio Pharmaceutical Co (BJSE:920729) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guangdong Winsun Bio Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Guangdong Winsun Bio Pharmaceutical Co's share price for today is ¥7.00.
Guangdong Winsun Bio Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.105.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Guangdong Winsun Bio Pharmaceutical Co EV-to-FCF Related Terms
Guangdong Winsun Bio Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangdong Winsun Bio Pharmaceutical Co EV-to-FCF Chart
Guangdong Winsun Bio Pharmaceutical Co Annual Data
BJSE:920729 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Guangdong Winsun Bio Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangdong Winsun Bio Pharmaceutical Co EV-to-FCF vs Biotechnology Industry
Guangdong Winsun Bio Pharmaceutical Co's current Enterprise Value is ¥1,861.5 Mil.
Guangdong Winsun Bio Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥52.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangdong Winsun Bio Pharmaceutical Co (BJSE:920729) has a EV-to-FCF of 35.49 as of Aug. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guangdong Winsun Bio Pharmaceutical Co and its competitors. This is 30% below median its historical median of 50.52. Over the past decade, Guangdong Winsun Bio Pharmaceutical Co's EV-to-FCF has ranged from 19.09 to 325.01. According to the industry distribution chart, Guangdong Winsun Bio Pharmaceutical Co ranks #225 out of 319 companies in the Biotechnology industry, placing it in the top 70.5%.
Is Guangdong Winsun Bio Pharmaceutical Co's EV-to-FCF too high?
Guangdong Winsun Bio Pharmaceutical Co's current EV-to-FCF of 35.49 is 30% below median its 10-year median of 50.52. Over the past 10 years, this metric has ranged from a low of 19.09 to a high of 325.01. The Biotechnology industry median EV-to-FCF is 16.98. Guangdong Winsun Bio Pharmaceutical Co's value of 35.49 is 109% above this industry median. Based on the distribution chart, Guangdong Winsun Bio Pharmaceutical Co ranks #225 out of 319 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Guangdong Winsun Bio Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guangdong Winsun Bio Pharmaceutical Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Guangdong Winsun Bio Pharmaceutical Co ranks #225 out of 319 companies for EV-to-FCF. This places Guangdong Winsun Bio Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 16.98. Guangdong Winsun Bio Pharmaceutical Co's value of 35.49 is 109% above this benchmark. Historically, Guangdong Winsun Bio Pharmaceutical Co's own EV-to-FCF has ranged from 19.09 to 325.01 over the past decade. While the company's 10-year median is 50.52 vs. the industry median of 16.98, Guangdong Winsun Bio Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.98, based on 319 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangdong Winsun Bio Pharmaceutical Co's current EV-to-FCF of 35.49 is 109% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guangdong Winsun Bio Pharmaceutical Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangdong Winsun Bio Pharmaceutical Co's current EV-to-FCF is 35.49, which is 30% below median its own 10-year median of 50.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangdong Winsun Bio Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guangdong Winsun Bio Pharmaceutical Co (BJSE:920729) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.67, compared to a current price of ¥7.00 — trading 23.5% above its estimated fair value. The current EV-to-FCF is 35.49, which is 30% below median its 10-year median of 50.52 and 109% above the Biotechnology industry median of 16.98. Guangdong Winsun Bio Pharmaceutical Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Guangdong Winsun Bio Pharmaceutical Co (BJSE:920729), the current EV-to-FCF is 35.49 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangdong Winsun Bio Pharmaceutical Co (BJSE:920729) Overvalued in 2026?
Based on GuruFocus' analysis, Guangdong Winsun Bio Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥7.00 is trading 23.5% above its estimated GF Value™ of ¥5.67.
GuruFocus considers Guangdong Winsun Bio Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for BJSE:920729:
EV-to-FCF: 35.49 (30% below median its 10-year median of 50.52)
GF Value™: ¥5.67 vs. price of ¥7.00 (23.5% above fair value)
Industry Position: 109% above the Biotechnology median (#225 of 319)
No single metric tells the full story. See the BJSE:920729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangdong Winsun Bio Pharmaceutical Co Ltd is involved in the field of veterinary biological products. It is an enterprise integrating research and development, production, sales, and service of veterinary biological products. It engages in the production of embryotoxin live vaccines, cytotoxic live vaccines, bacterial live vaccines, avian influenza inactivated vaccines, cytotoxic inactivated vaccines, embryotoxin inactivated vaccines, bacterial inactivated vaccines, swine fever live vaccines (rabbit source); veterinary use of Biological products.
74GF Score
Get the complete analysis for BJSE:920729
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920729 has been successfully added to your 
